PR21 at #ESMO2026:
Lu-177 PSMA-617 showed better patient-reported QoL than docetaxel in mCRPC.
At week 30, FACT-P change was +4.7 vs −8.3 (P<0.001).
Side-effect bother: 15.4% vs 40.7%.
No significant rPFS difference.
https://oncodaily.com/oncolibrary/radiotherapy/pr21-trial
@myESMO
22 浏览 · 1 赞 · 0 转发 · 0 回复
BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer
https://esmocongress.esmo.orgAnbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：OncoDaily RT · x.com